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Enteric infections induced by pathogens like Vibrio cholerae and enterotoxigenic
Escherichia coli (ETEC) remain a massive burden in developing countries with increasing
morbidity and mortality rates. Previously, we showed that the immunization with
genetically detoxified outer membrane vesicles (OMVs) derived from V. cholerae elicits
a protective immune response based on the generation of O antigen antibodies, which
effectively block the motility by binding to the sheathed flagellum. In this study, we
investigated the potential of lipopolysaccharide (LPS)-modified and toxin negative OMVs
isolated from V. cholerae and ETEC as a combined OMV vaccine candidate. Our results
indicate that the immunization with V. cholerae or ETECOMVs induced a species-specific
immune response, whereas the combination of both OMV species resulted in a high-titer,
protective immune response against both pathogens. Interestingly, the immunization with
V. cholerae OMVs alone resulted in a so far uncharacterized and cholera toxin B-subunit
(CTB) independent protection mechanism against an ETEC colonization. Furthermore,
we investigated the potential use of V. cholerae OMVs as delivery vehicles for the
heterologously expression of the ETEC surface antigens, CFA/I, and FliC. Although we
induced a detectable immune response against both heterologously expressed antigens,
none of these approaches resulted in an improved protection compared to a simple
combination of V. cholerae and ETEC OMVs. Finally, we expanded the current protection
model from V. cholerae to ETEC by demonstrating that the inhibition of motility via
anti-FliC antibodies represents a relevant protection mechanism of an OMV-based ETEC
vaccine candidate in vivo.
Keywords: outer membrane vesicles, Vibrio cholerae, enterotoxigenic Escherichia coli, vaccines, enteric
pathogens, combined vaccine
Introduction
Enteric infections associated with diarrhea remain a leading global health problem. They have
been recognized as the first leading cause of neonatal diarrhea and the second major cause
of infant mortality in developing countries (Rao et al., 2003; Bryce et al., 2005; Levine, 2006).
Besides, diarrheal disease also represents the most common health problem in travelers to
low resource countries. Almost half of all diarrheal infections are caused by the enterotoxin
producing Gram-negative bacteria Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC)
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(Sánchez and Holmgren, 2005; WHO, 2006). In general the
pathophysiology of both pathogens is quite similar. They enter
the human host via contaminated food or water, passage through
the stomach and finally reach the intestinal tract representing
the primary colonization site. Both pathogens attach to the
mucosal surface via surface-associated structures, i.e., the toxin-
coregulated pilus in case of V. cholerae or various fimbrial
colonization factors (CFs) in case of ETEC. The secretory
diarrhea is mainly caused by closely related AB-toxins known
as cholera toxin (CT) or heat-labile enterotoxin (LT) for V.
cholerae or ETEC, respectively (Faruque et al., 1998; Sánchez and
Holmgren, 2005; Fleckenstein et al., 2014).
V. cholerae is the causative agent of the severe secretory
diarrheal disease cholera, which can lead to death within
hours, if left untreated (Koch, 1884). Although oral and
intravenous rehydration therapies are effective, the access to
these treatments is limited in regions with poor infrastructure
or in the course of rapidly spreading outbreaks (Harris et al.,
2012). Thus, the WHO estimates 3–5 million cholera cases
and 100,000–120,000 cholera deaths every year (WHO, 2010).
While cholera might be the more severe disease, infections
with ETEC are responsible for the largest number of diarrheal
episodes. Conservative estimates suggest that ETEC strains are
incriminated as the cause of 280–400 million diarrheal cases,
resulting in 300,000–500,000 deaths every year mostly in children
under the age of 5 years. ETEC is also the major cause of
travelers’ diarrhea, being responsible for one-third to one-
half of all diarrheal episodes in travelers to Africa, Asia, and
Latin America, including both civilian and military personnel
(WHO, 2006). These epidemiological numbers highlight the
desperate need for a cheap and effective vaccine against both
pathogens.
Currently, there are two types of oral cholera vaccines
available (WHO, 2010). Dukoral is most widely used and
consists of heat- or formalin-killed whole cells of V. cholerae
serogroup O1 and a recombinant produced CTB. Through
its CTB component, it represents the only available vaccine,
which affords short-term cross-protection against LT producing
ETEC strains (Clemens et al., 1988, 1990; Peltola et al., 1991;
Jertborn et al., 1992, 1993, 1994). However, the short shelf life,
high costs, and its need for cold-chain distribution restrict the
vaccine for broad use in developing countries (Cumberland,
2009; Bishop and Camilli, 2011). Shanchol and mORCVAX
are closely related and use identical strains but are produced
by independent manufacturers and diverging methods. These
vaccines are thought to confer longer term protection, but still
require a cold-chain. In addition, they do not contain the CTB
subunit and will therefore not protect against ETEC (WHO,
2010). In contrast, there is no licensed vaccine available against
ETEC (Svennerholm and Lundgren, 2012). Several ETEC vaccine
strategies have focused on a relatively small group of antigens,
namely, plasmid encoded surface antigens known as CFs or
LT. Along with attempts to develop LT-based toxoids, oral live
attenuated, or inactivated whole cell vaccines overexpressing the
most prevalent CFs have been the central focus of the vaccine
development and are currently in different clinical trials (Tobias
et al., 2010a,b, 2011; Harro et al., 2011; Turner et al., 2011; Darsley
et al., 2012; Byrd and Boedeker, 2013; Holmgren et al., 2013;
Lundgren et al., 2013).
Recently, we introduced and characterized outer membrane
vesicles (OMVs) derived from V. cholerae as an alternative
vaccine candidate against cholera (Schild et al., 2008, 2009;
Bishop et al., 2010; Leitner et al., 2013). OMVs are naturally
released by various Gram-negative bacteria and largely reflect the
composition of the outer membrane (OM) and the periplasm of
their donor bacterium (Gankema et al., 1980; Beveridge, 1999;
Ellis and Kuehn, 2010). Thus, they represent a combination of
various native surface antigens, which are highly immunogenic as
well as self-adjuvant. For these reasons, OMVs have been studied
for their immunogenic and protective properties of several
bacterial species. In case of V. cholerae OMVs, the induction
of a specific, high-titer protective immune response against
the respective pathogen upon intranasal immunization of mice
has been successfully demonstrated (Schild et al., 2008, 2009).
Further studies characterized the O antigen to be the dominant
protective antigen and revealed a protection mechanism based
on inhibition of motility by anti-O antigen antibodies binding to
the sheathed flagellum of V. cholerae (Bishop et al., 2010; Leitner
et al., 2013). Interestingly, a recent study by Roy et al. indicated
that immunization with ETEC OMVs derived from a flagellar
mutant also induced a robust immune response in the murine
model (Roy et al., 2011).
Intrigued by this report, the present study aimed to create
an improved, combined vaccine against the two major bacterial
infectious agents of diarrheal diseases: V. cholerae and ETEC.
Our results indicate, that immunization with a mixture of
detoxified and enterotoxin-negative OMVs derived from V.
cholerae and ETEC induces a high-titer, protective immune
response against both pathogens. Interestingly, V. cholerae
OMVs alone already induce a so far uncharacterized and CTB
independent protection against ETEC colonization. Additionally,
we used V. cholerae OMVs as antigen delivery vehicles for
the heterologously expressed ETEC surface antigens CFA/I and
FliC. Although a detectable immune response against both
heterologously expressed ETEC antigens was induced, none of
these approaches resulted in an improved protection compared
to a simple V. cholerae and ETEC OMVmixture. Finally our data
indicates that inhibition of motility based on anti-FliC antibodies
might also play a role in the protectionmechanism against ETEC.
Materials and Methods
Bacterial Strains, Plasmids, and Growth
Conditions
Bacterial strains and plasmids used in this study are listed in
Table 1; oligonucleotides are listed in Table 2. V. cholerae, AC53,
a spontaneous streptomycin (Sm)-resistant mutant of the clinical
isolate E7946 (O1 El Tor Ogawa), or ETEC H10407-S, a Sm-
resistant mutant of the clinical isolate H10407, were used as
wild type strains. E. coli strain DH5αλpir and SM10λpir were
used for genetic manipulations. If not noted otherwise, strains
were cultured in Luria Bertani (LB) broth or on LB broth
agar plates with aeration at 37◦C. For optimal induction of the
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TABLE 1 | Strains and plasmids used in this study.
Strain or plasmid Genotype/resistance/description References
E. COLI
DH5αλpir F−8801lacZ1M151(argF lac)U169 deoR recA1 endA1 hsdR17 (r−Km
+
K ) supE44 thi-1 gyrA69
relA1, λpirR6K, Apr
Hanahan, 1983
SM10λpir thi thr leu tonA lacY supE recA::RPA-2-Te::Mu λpirR6K, Kmr Miller and Mekalanos, 1988
EWT H10407-S, wild type ETEC strain; serotype O78:H11; CFA/I LT+ STh+ STp+, Smr Evans and Evans, 1973
E1msbB H10407 1msbB; Smr This study
E1msbB1eltA H10407 1msbB1eltAB eltA::pGP704; Smr, Apr This study
V. CHOLERAE
VWT AC53, wild type V. cholerae strain serogroup, O1; biotype, El Tor; serotype, Ogawa;
spontaneous Smr mutant of E7946; clinical isolate from Bahrain 1978; hapR+, Smr; used for
previous immunization studies (Schild et al., 2008, 2009; Bishop et al., 2010, 2012; Leitner
et al., 2013)
Miller et al., 1989
V1msbB1ctxAB AC53 1msbB1ctxAB; Smr This study
V1msbB1ctxAB1flaA AC53 1msbB1ctxAB1flaA; Smr This study
PLASMIDS
pCVD442 ori6K mobRP4 sacB, Apr Donnenberg and Kaper, 1991
pGP704 ori6K mobRP4, Apr Miller and Mekalanos, 1988
p1ctxAB pCVD442::1RS1-CTX phage-TLC of AC53, Apr Bishop et al., 2010
p1msbB_E pCVD442::1msbB of H10407, Apr This study
p1eltAB pCVD442::1eltAB of H10407, Apr This study
eltA::pGP704 Insertion of pGP704 in eltA of H10407 This study
p1flaA pCVD442::1flaA of AC53, Apr This study
pCFA/I CFA/I of H10407 cloned into pBAD18, Kmr This study
pCfaB CfaB of H10407 cloned into pQE30, Apr This study
pFliC 1320-bp fliC fragment cloned into pQE30, Apr This study
pFlaA-FliC Hybrid construct consisting of FlaA (first 47 aa) of AC53 and FliC (last 440 aa) of H10407
cloned into pBAD18, Kmr
This study
pAR181 gfpmut3b* gene under transcriptional control of the E. coli rrnB-P1 promoter Sherlock et al., 2004
enterotoxins, V. cholerae was grown in AKI broth and ETEC
was grown in CYE-G media [casamino acids (30 g/l), yeast
extract (3 g/l), K2HPO4 (0.5 g/l), glucose (2 g/l) (pH 8), (Sack
et al., 1980; Iwanaga and Yamamoto, 1985; Iwanaga et al., 1986;
Leitner et al., 2013)]. To induce CFA/I expression, ETEC was
cultivated on CFA plates (1% casamino acids, 0.15% yeast extract,
0.005% MgSO4, 0.0005% MnCl2, 1.5% agar) (Evans et al., 1977;
Horstman and Kuehn, 2000; Baker et al., 2009). If required,
antibiotics, or other supplements were used in the following
final concentrations: Sm, 100µg/ml; Ampicillin (Ap), 100µg/ml
or in combination with other antibiotics 50µg/ml; kanamycin
(Km), 50µg/ml; chloramphenicol (Cm), 30µg/ml; IPTG, 1mM;
arabinose (Ara), 0.02%; glucose (Gluc), 0.2%; sucrose (Suc), 10%.
Construction of Deletion Mutants and Expression
Plasmids
Genetic manipulations including the isolation of chromosomal,
plasmid, or PCR product DNA, PCR assays, the construction
of in-frame deletion mutants, insertion mutants, and expression
plasmids were carried out as described previously using
derivatives of pCVD442, pGP704, or pBAD18 (Fengler et al.,
2012; Leitner et al., 2013). The expression plasmid pFliC
was constructed using the oligonucleotides flic_BamHI_fw and
flic_SalI_rev for amplifying the respective gene, digested with
BamHI and SalI, and ligated into pQE30, which has been
digested with the same enzymes. The fusion protein FlaA-FliC
was generated by SOE PCR (splicing by overlap extension), using
chromosomal DNA of AC53 and H10407-S as a template and
the oligonucleotide pairs flaAfliC_SacI_1 and flaAflic_2 as well
as flaAfliC_3 and flaAfliC_XbaI_4 (Horton et al., 1989). The
generation of overlapping regions allowed the annealing of the
two PCR fragments in a further PCR reaction. The resulting
PCR product was ligated into the SacI/XbaI-digested pBAD18.
Introducing the GFP expression plasmid, pAR181, into the wild
type strain of ETEC, generated a GFP expression strain.
Preparation of OMVs, Whole Cell Lysates (WCL),
and LPS
V. cholerae as well as ETEC OMVs were isolated as previously
described (Schild et al., 2008; Leitner et al., 2013). WCL
were prepared as previously published using 0.1mm
glass beads in combination with a PowerLyzer™ 24 (MO
BIO Laboratories, Inc.), applying three 1min cycles at
3400 rpm with 1min intervals on ice between each cycle
(Roier et al., 2012, 2013). The protein concentrations of
the OMV preparations were determined by measuring the
absorbance at 260 and 280 nm using a Beckman Coulter DU730
spectrophotometer in combination with a TrayCell (Hellma) and
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TABLE 2 | Oligonucleotides used in this study.
Primer Name Sequence (5′–3′)a
msbB_E_SacI_1 TTGAGCTCTTAACCAGCGCCGAAGTG
msbB_E_BamHI_2 TAGGATCCCATGCTTTTCCAGTTTCGGAT
msbB_E_BamHI_3 TTGGATCCTAAAAAAGCCTCTCGCGA
msbB_E_XbaI_4 TTTCTAGAGCTGTGATGCTGTCTGC
eltAB_SacI_1 TTGAGCTCTCCGGCAGGGTGAAGAC
eltAB_BamHI_2 TTGGATCCCATCGAGGAAAACTTATATAT
eltAB_BamHI_3 TTGGATCCGAAAACTAGTTTGCTTTAAAAG
eltAB_XbaI_4 TTTCTAGACATCATCGTTGGTCGTGAC
eltA_XbaI_1 ATTCTAGACCCCCAGATGAAAT
eltA_SacI_2 TTGAGCTCGCCTCTTAACTTTTGATTGATA
flaA_SacI_1 TTGAGCTCAAATGGCTATCAGTTAGAGC
flaA_BamHI_2 TTGGATCCCATAGTTTGCTCTCCTATCG
flaA_BamHI_3 TTGGATCCTAGTTCACGGTACCTTCATT
flaA_XbaI_4 TATCTAGATGAATCGCAACACGGTCAG
CFAI_StuI_1 ATAGGCCTTGATTTATTATTGATGGAAGCTCA
CFAI_NheI_2 ATGCTAGCTCTAGAGTGTTTGACTACTTGG
CfaB_SphI_fw ATGCATGCGTAGAGAAAAATATTACTGTAGC
CfaB_HindIII_rv TATAAGCTTAAGAATCAGGATCCCAAAGT
Flic_BamHI_fw TAGGATCCCAGGCGATTGCTAACCGTT
Flic_SalI_rv TAGTCGACACGCAGCAGAGACAGTACG
FlaA_FliC_SacI_1 TTTGAGCTCGAACTCGATAGGAGAGCAA
FlaA_FliC_2 AACGGTTAGCAATCGCCTGGCCTGCCGCGTCATCTTT
FlaA_FliC_3 AAAGATGACGCGGCAGGCCAGGCGATTGCTAACCGTT
FlaA_FliC_XbaI_4 TAATCTAGAGGTTGAGCGATAAGTGTAAA
qRT-PCRb
Il6-fw GAGGATACCACTCCCAACAGACC
Il6-rv AAGTGCATCATCGTTGTTCATACA
Tnf-alpha-fw CATCTTCTCAAAATTCGAGTGACAA
Tnf-alpha-rv TGGGAGTAGACAAGGTACAACCC
Il1b(M)-fw CAACCAACAAGTGATATTCTCCATG
Il1b(M)-rv GATCCACACTCTCCAGCTGCA
36B4-fw GCTTCATTGTGGGAGCAGACA
36B4-rv CATGGTGTTCTTGCCCATCAG
aRestriction sites are underlined.
bAccording to Leitner et al. (2013).
the Warburg-Christian equation. The purification of the LPS of
V. cholerae as well as ETEC cultures and the estimation of their
concentrations were performed as previously reported (Leitner
et al., 2013).
Purification of Proteins and Immunization
The His-tagged proteins were purified using the expression
plasmid pCfaB and pFliC as described previously (Leitner
et al., 2013). In order to generate high-titer IgG1 antisera
against CfaB, the purified His-tagged protein (100µg protein per
immunization) was used to intraperitoneally immunize mice on
days 0, 14, and 28. Finally, sera were collected on day 40.
Trichloroacetic Acid Precipitation (TCA)
To precipitate the CT as well as the LT, cultures were grown under
toxin expressing conditions and centrifuged (6500 × g, 25min,
4◦C). The toxin-containing supernatant was collected, filtered
and mixed with a 100% TCA-solution (final concentration 20%).
After centrifugation (22,500 × g, 60min, 4◦C), the pellet was
washed twice with acetone, air-dried, dissolved in PBS (pH 7.4)
and stored at−20◦C.
TNF-α, IL-1ß, and IL-6 Induction Assay
The stimulation of RAWmacrophages with ETECOMVs derived
either fromWT or1msbB (1µg/ml), the cDNA synthesis as well
as the qRT-PCR were performed as described previously (Leitner
et al., 2013).
Animals
Female BALB/c mice (Charles River Laboratories) were used
in all experiments in accordance with the rules of the ethic
committee at the University of Graz and the corresponding
animal protocol, which has been approved by the Austrian
Federal Ministry of Science and Research Ref. II/10b. Mice were
housed with food and water ad libitum and monitored under the
care of full-time staff. All animals were acclimated for 1 week
before any procedures were carried out and were approximately
9 weeks old at the start of the immunization.
OMV Immunization Protocol and Neonatal
Challenge with V. cholerae and ETEC
Nine-week-old female mice were intranasally immunized with
either one OMV type (25µg) or with an OMV mixture (12.5µg
each) in PBS at days 0, 14, and 28 as described previously
(Schild et al., 2008; Leitner et al., 2013). A group of sham
(PBS)-immunized control mice were housed in parallel with the
immunized mice for the duration of each experiment. Mice were
anesthetized by inhalation of isoflurane gas (2.5%) prior to all
immunizations. Overall two independent immunization rounds
for each immunization group were performed with at least three
mice per group. Comparison of the results from the independent
immunization rounds revealed no differences in the induction of
a humoral immune response or the reduction of the colonization
level in the respective immunization group.
Non-vaccinated control and immunized mice were mated at
day 41, and 5- to 6-day-old neonates were challenged either with
V. cholerae or ETEC according to a previously published method
with slight modifications (Leitner et al., 2013). This indirect
protection assay was used, since adult mice are only successfully
colonized by V. cholerae after pretreatment with antibiotics to
decrease the bacterial gut flora. For the preparation of the ETEC
inoculum, bacteria were streaked on an LB-Sm plate (2 days prior
to the infection), transferred to a CFA-Sm plate (16 h prior to
the infection), diluted to the appropriate density in LB broth,
and plated to determine the number of input CFU. In order to
gain challenge data for both organisms, neonates from a given
litter were splitted and orally infected with either V. cholerae or
ETEC. The exact input doses ranged from 6.8× 104 to 1.6× 105
CFU/mouse for V. cholerae or 5.7× 104 to 1.5× 105 CFU/mouse
for ETEC, which is in both cases at least 100-fold above the 50%
infective dose (ID50) (Goldhar et al., 1986; Schild et al., 2008).
Infected mice were given back to their respective dams. At 24 h
post-infection, neonates were sacrificed by cervical dislocation,
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and the small intestine was removed from each neonatal mouse
by dissection and was mechanically homogenized in 1ml LB
with 20% glycerol. Appropriate dilutions were plated on LB-Sm
plates to determine viable counts. The limit of detection was 10
CFU/small intestine.
Additionally, a passive protection study using purified antisera
in combination with the infant mouse model was performed
with slight modifications as previously described (Leitner et al.,
2013). The anti-IgG1 titer of each serum was determined via
ELISA using the appropriate coating antigen (OMVs, His-Flic)
to allow an adjustment to equal concentration in the assay. For
the inoculum, an ETEC culture was adjusted to an OD600 of
0.003 and subsequently mixed in a 2:1 ratio with appropriate
dilutions of non-vaccinated control, anti-V1msbB1ctxABOMV,
anti-E1msbB1eltAOMV, anti-OMVmix, or anti-FliC (Creative
Diagnostics) serum to achieve a final IgG1 concentration of
9µg/ml. After 10–30min incubation at room temperature,
neonatal mice born to naive dams were infected with an
infectious dose of approximately 8 × 104 CFU/mouse. At 24 h
post-infection, neonates were sacrificed and the colonization was
determined as described above. To analyze the viability of ETEC
in presence of anti-FliC sera, ETEC, and antisera were mixed as
described above. After 30min incubation at room temperature,
samples were rigorously vortexed to dissolve potential aggregates
and appropriate dilutions were plated for CFU counts.
Preparation of Blood, Stool, and Milk Samples
Blood samples as well as fecal pellets were collected from
immunized and sham-immunized adult mice throughout the
immunization study and processed as previously described to
monitor the induced immune response (Schild et al., 2008,
2009). Additionally, the stomach contents of infected mice were
collected, pooled for each litter and the Igs were extracted by
adding 300µl of extraction buffer [PBS, 0.01% sodium azide,
5% fetal calf serum, one tablet complete EDTA-free protease
inhibitor cocktail (Roche) per ml] per 100mg of stomach
content. The samples were disrupted by homogenization,
centrifuged, and the clear supernatant (milk) was stored
at−70◦C.
SDS-PAGE and Immunoblot Analysis
To analyze the protein content of OMVs, the standard sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
procedure in combination with 15% gels and the Prestained
Protein Marker Broad Range (New England BioLabs) as a
molecular mass standard were used. Approximately 7µg of
each sample was loaded and either stained according to the
procedure of Kang et al. or transferred to a nitrocellulose
membrane (Amersham) for immunoblot analysis, which was
performed as described previously (Kang et al., 2002; Roier et al.,
2012).
ELISA
Temporal immune responses of different Igs, half-maximum
total Ig titers and mucosal immune responses to OMVs
(5µg/ml in PBS, pH 7.4) derived from V. cholerae and
ETEC as well as the determination of the half-maximum
total Ig titers to LPS (7µg/ml in PBS, pH 7.4) of both
organisms and the quantification of the IgG1 levels of
purified proteins like His-CfaB (7µg/ml in 25mM Tris-
HCl, pH 7.5) and His-FliC (7µg/ml in PBS, pH 7.4)
were carried out essentially as described previously, using
horseradish peroxidase-conjugated goat anti-mouse antibodies
(BD Biosciences) as secondary antibodies in combination with
the TMB peroxidase substrate reagent set (BioLegend) (Roier
et al., 2012; Leitner et al., 2013). Optical densities were monitored
at 450 nm with a FLUOstar Omega microplate reader (BMG
Labtech).
Motility Assay
The motility assay was performed with slight modifications
as previously described (Leitner et al., 2013). To allow an
adjustment to equal concentrations in the assay, the anti-IgG1
titer of each serum derived from mice immunized with OMVs
and of the commercially available anti-FliC antibody (Creative
Diagnostics) was determined via ELISA using the appropriate
coating antigen (OMVs or His-FliC). Sera of the non-vaccinated
control group were diluted by the lowest dilution factor needed
for the immune serum to obtain 6µg/ml anti-IgG1 titer in the
same experiment. A GFP expressing ETEC strain was taken from
a CFA plate supplemented with Cm, adjusted to an OD600 of
0.8 and mixed with heat-inactivated serum (56◦C, 30min) in a
2:1 ratio to achieve a final IgG1-titer of 6µg/ml. After 10min
of incubation, 4µl were placed on a slide under a coverslip
and viewed with 60-x objective using a Nikon Eclipse TE300
microscope. The images were taken using the software NIS-
Elements AR3.0.
Statistical Analysis
Data were analyzed using the Mann–Whitney U test or
a Kruskal–Wallis test followed by post-hoc Dunn’s multiple
comparisons. Differences were considered significant at P <
0.05. For all statistical analyses, GraphPad Prism version 4.0a was
used.
Results
Characterization of Detoxified and Enterotoxin
Negative Mutants in V. cholerae and ETEC
We recently demonstrated that OMVs derived from V. cholerae
lacking one functional secondary lipid A acyltransferase, MsbB
(also referred to as LpxN), exhibit 50% less endotoxicity and
retain their potential to induce a high-titer, protective immune
response (Leitner et al., 2013). Encouraged by these results,
we constructed a 1msbB mutant strain in ETEC (E1msbB)
to reduce the endotoxicity of the potential ETEC OMVs as
vaccine candidates. To compare the endotoxicity of OMVs
derived either from ETEC wild type (EWT) or the E1msbB
mutant, the expression levels of the inflammatory markers TNF-
α, IL-1ß, and IL-6 of OMV-stimulated RAW macrophages were
analyzed (Figure 1). Non-stimulated RAW macrophages served
as control. In concordance with previous results, the expression
of all three cytokines was greatly induced by EWT OMVs,
ranging from 18-fold for TNF-α to approximately 7500-fold
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FIGURE 1 | E1msbB OMVs are less endotoxic. Shown is the induction of
TNF-α (A), IL-1β (B), and IL-6 (C) in RAW macrophages after treatment with
OMVs (1µg/ml) derived from EWT or E1msbB compared to the
non-stimulated control group and normalized to the housekeeping gene 36B4.
Each data set represents the median from at least six independent
experiments. The error bars indicate the interquartile range of each data set.
Significant differences between the data sets are marked by asterisks
(P < 0.05; Mann–Whitney U test).
for IL-1ß and almost 2000-fold for IL-6. In contrast, treatment
with E1msbB OMVs induced a significantly weaker induction
of an inflammatory response, which reached 10–50% of the level
detected for EWT OMVs. This indicates a lower endotoxicity of
the underacylated, detoxified LPS of E1msbBOMVs due to their
reduced stimulation of TLR-4 (Somerville et al., 1996).
Using the V1msbB and E1msbB mutants as a platform, we
constructed OMV donor strains by additional deletion of both
CT subunits in V. cholerae as well as the catalytically active A
subunit of LT (LTA) in ETEC. The B subunit of LT was retained
functional due to its reported adjuvant efficacy as well as it
may provide cross-protection against V. cholerae as a result of
the closely related AB-toxins of both pathogens (Clements and
Finkelstein, 1978; Cheng et al., 1999). To visualize the absence
of both CT subunits as well as LTA in the mutant strains, TCA
precipitated culture supernatants were analyzed via immunoblot
using the LT cross-reactive anti-CT polyclonal antisera (Sigma).
This enabled the detection of both toxin subunits with the
corresponding band at approximately 27 kDa for the A subunit
and 11.6 kDa for the B subunit (Sixma et al., 1991) in the wild type
samples of V. cholerae (VWT) and EWT (Figures 2A,B, lane 1).
In contrast these bands were not detected in the samples derived
from V1msbB1ctxAB and E1msbB1eltA mutant, confirming
the absence of both CT subunits and the absence of LTA,
respectively (Figures 2A,B, lane 2). The additional detection of
bands are likely to be either cross-reacting bands appearing in
wild type and respective mutant samples or might be CT-or LT-
aggregates, in case of bands absent in the respective non-toxin
mutant.
Furthermore, we analyzed the protein profile of the purified
OMVs derived from VWT, V1msbB1ctxAB, EWT, and
E1msbB1eltA by SDS-PAGE in combination with Kang‘s
staining method (Figure 3). In concordance with previous data
on V. cholerae OMVs, no obvious differences could be observed
between OMVs from VWT and V1msbB1ctxAB (Figure 3,
lanes 1 and 2) (Leitner et al., 2013). The protein profile of
FIGURE 2 | Detection of CT and LT using immunoblot analysis.
Immunoblots were loaded with TCA precipitated supernatant of VWT (A, lane
1), V1msbB1ctxAB (A, lane 2), EWT (B, lane 1) or E1msbB1eltA (B, lane 2)
and incubated with a LT cross-reactive anti-CT polyclonal antiserum (Sigma).
The arrows to the right indicate the sizes of the A-subunit (a) as well as the
B-subunit (b) of CT and LT. Lines to the left indicate the molecular masses of
the protein standards in kDa. A corresponding Kang-stained gel (Kang et al.,
2002) loaded with equal amounts as the immunoblot served as loading control
and is presented in Figure S1.
FIGURE 3 | OMV protein profiles of the OMV donor strains. Depicted are
the protein profiles of purified OMVs derived from VWT (lane 1),
V1msbB1ctxAB (lane 2), EWT (lane 3) and E1msbB1eltA (lane 4). Samples
(approximately 7µg protein each) were separated by SDS-PAGE (15% gels)
and protein bands were visualized according to Kang et al. (2002). Lines to the
left indicate the molecular masses of the protein standard in kDa.
ETEC OMVs exhibits more high-molecular-weight bands, with
the most prominent one at approximately 50 kDa (Figure 3,
lanes 3 and 4). In comparison to the EWT OMV protein
profile, the mutant lacks one band of approximately 27 kDa,
which might be due to the eltA deletion. In general, the most
abundant protein bands are present between 25 and 58 kDa in
all OMV vaccine candidates (Figure 3, lanes 1–4). The LPS of
EWT and E1msbB1eltA was also isolated and analyzed by silver
staining, but no significant changes could be observed (data not
shown).
Frontiers in Microbiology | www.frontiersin.org 6 August 2015 | Volume 6 | Article 823
Leitner et al. OMV vaccine against enteric pathogens
Immunization with OMVs of V. cholerae and
ETEC Induces a Robust Species-specific
Immune Response
In order to investigate the immune response upon OMV
immunization against both enteric pathogens, we intranasally
immunized mice with OMVs derived from V1msbB1ctxAB,
EWT, E1msbB1eltA strains or with a 1:1 mixture of
V1msbB1ctxAB and E1msbB1eltA OMVs according to
our standard immunization protocol (Schild et al., 2008). Mice
sham-immunized with PBS served as non-vaccinated control
group. To monitor the immune responses in sera of immunized
and non-vaccinated mice by ELISA, OMVs derived from VWT
or EWTwere used as coating material. This allowed the detection
of species and/or cross-species specific OMV antigen antibody
responses. The temporal IgM, IgG1 and IgA responses in sera
to OMVs derived from V. cholerae or ETEC are shown in
Figure 4 for all immunization groups. The antibody titers of the
non-vaccinated control group were determined for day 0 and day
86 and remained at very low levels for both time points. At day
0, the isotype-specific antibody titers to OMVs derived from V.
cholerae or ETEC were relatively low and showed no significant
differences between the tested immunization groups (P < 0.05;
Kruskal–Wallis test and post-hoc Dunn’s multiple comparisons).
Mice immunized with V1msbB1ctxAB OMVs or the OMV
mix induced an isotype-specific immune response against
V. cholerae OMVs. In contrast, mice immunized with EWT,
E1msbB1eltA OMVs or the OMV mix showed a pronounced
increase of IgM, IgG1, and IgA titers against ETEC OMVs. Thus,
immunization with V. cholerae or ETEC OMVs seems to induce
a species-specific immune response. In general, the induction of
an immune response was characterized by an Ig titer increase
during the vaccination period with a peak at day 38 or day 78.
Especially, IgG1 and IgA titers remained stable or even increased
between day 38 and 78, which indicates the induction of a robust,
long-lasting immune response. Mice immunized with EWT or
E1msbB1eltA OMVs showed comparable induction patterns,
indicating that the reduction of endotoxicity and the deletion of
eltA did not affect the overall immunogenicity of ETEC OMVs.
To further characterize the induced humoral immune
response in sera, the half-maximum total Ig titers against V.
cholerae or ETEC OMVs as well as against purified V. cholerae
or ETEC LPS were quantified (Figures 5A,B). In addition,
the mucosal immune response against V. cholerae and ETEC
was analyzed by monitoring the secretory IgA titers in fecal
pellets of immunized mice as well as the IgG1 titers in the
stomach content of neonates, displaying the Ig transfer from the
immunized dams to the offspring via breast milk (Figures 5C,D).
As previously noted (Schild et al., 2009), the ELISA results
of the stomach contents exhibited more variation than those
for fecal pellets. In general, a similar induction pattern for the
sera samples, fecal pellets, and milk samples was observed for
each immunization group. In comparison to the non-vaccinated
control group the VmsbB1ctxAB OMV immunization group
showed significant higher titers against V. cholerae, but not
against ETEC. In contrast, the groups immunized with EWT
or E1msbB1eltA OMVs exhibited a significant induction of Ig
titers against ETEC, but not against V. cholerae, if compared
FIGURE 4 | Temporal immune responses to V. cholerae and ETEC
OMVs. Shown are the median titers over time of IgM (A,D), IgG1 (B,E) and
IgA (C,F) antibodies to OMVs derived from V. cholerae (A–C) and ETEC (D–F)
in sera from mice intranasal immunized with V1msbB1ctxAB OMVs (dashed
and dotted line), EWT OMVs (dashed line), E1msbB1eltA OMVs (dotted line),
an OMV mix (black solid line) and from the non-vaccinated control group (gray
solid line) (n = 8 for each group). The error bars indicate the interquartile range
of each data set for each time point.
to the non-vaccinated control group. In concordance with the
temporal immune response only the OMV mix group induced
a robust immune response against both pathogens. Notably,
this group exhibited a similar immune response for all three
isotypes in comparison to the respective immunization group
receiving only a single OMV type (i.e., V1msbB1ctxAB OMVs,
E1msbB1eltA OMVs, or EWT OMVs) and the respective
coating material. These results suggest no adverse effects by
mixing V. cholerae and ETEC OMVs regarding their induction
of a species-specific immune response. Finally, immunoblot
analysis using whole cell lysates (WCL) and OMVs derived from
V. cholerae and ETEC as antigens were used to analyze the
specificity of the antibody response against proteins present in
the respective samples. These immunoblots were incubated with
sera collected at day 86 from one representative mouse of each
immunization group as well as from the non-vaccinated control
group (Figure 6). No bands were detected on immunoblots
using sera of the non-vaccinated control group mice (data
not shown). Immunoblots incubated with sera from groups
immunized with V. cholerae OMVs allowed detection of bands
in the protein profile of V. cholerae, whereas no bands were
detected against ETEC. Immunoblots incubated with sera from
the EWT or E1msbB1eltA OMV immunization group revealed
various detectable bands in the protein profile of ETEC, but only
low-intensity bands for V. cholerae samples. This is concordant
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FIGURE 5 | Quantification of the immune response against V.
cholerae and ETEC induced in OMV-immunized mice. (A,B)
Half-maximum total Ig titers to OMVs (A) derived from V. cholerae and
ETEC as well as to purified V. cholerae or ETEC LPS (B) in sera
collected at day 86 from mice intranasal immunized with
V1msbB1ctxAB OMVs, EWT OMVs, E1msbB1eltA OMVs, and an
OMV mix (n = 8 for each group). (C) Median IgA titers to OMVs derived
from V. cholerae and ETEC extracted from fecal pellets collected at day
86 from the immunization groups (V1msbB1ctxAB OMVs, EWT OMVs,
E1msbB1eltA OMVs, and the OMV mix) as well as from the
non-vaccinated control group (n = 8 for each group). (D) IgG1 titers to
OMVs derived from V. cholerae and ETEC in stomach contents
collected from litters born from intranasal immunized female mice of the
immunization groups (V1msbB1ctxAB OMVs, EWT OMVs,
E1msbB1eltA OMVs, and the OMV mix) as well as the non-vaccinated
control group during the challenge period (day 67–78). The error bars
indicate the interquartile range of each data set and the hash key that
the result of the data set was below the limit of detection. Significant
differences between the data sets are marked by asterisks (P < 0.05;
Kruskal–Wallis test and post-hoc Dunn’s multiple comparisons).
with the ELISA results and suggests no significant induction of
a cross-species-specific antibody response by using just OMVs
from one species. Immunoblots incubated with sera of the
OMV mix group showed intensive bands against V. cholerae
and ETEC samples, highlighting the induction of an immune
response against both pathogens. In addition, the OMV mix
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FIGURE 6 | Characterization of the antibody response against surface
proteins of V. cholerae and ETEC in sera from OMV-immunized mice.
Representative immunoblots were loaded with V. cholerae (VWT) as well as
ETEC (EWT) whole cell lysates (WCL) and OMVs (approximately 7µg protein
each) as indicated above each blot and incubated with sera collected at day
86 from mice immunized with V1msbB1ctxAB OMVs (A), EWT OMVs (B),
E1msbB1eltA OMVs (C), and an OMV mix (D). Lines to the left indicate the
molecular masses of the protein standards in kDa. A corresponding
Kang-stained gel (Kang et al., 2002) loaded with equal amounts as the
immunoblot served as loading control and is presented in Figure S2.
and the V1msbB1ctxAB OMV immunization group showed
comparable band patterns against V. cholerae samples. The
same could be observed for the OMV mix, the EWT as well
as E1msbB1eltA OMV immunization groups against ETEC
samples. Thus, the OMV mix group induced a similar specificity
of the immune response on the protein level, if compared to the
individual species-specific immune response upon immunization
with either V. cholerae or ETEC OMVs. In general, immunoblots
loaded with WCL and OMV samples derived from the same
strain revealed similar patterns, but the intensity of the detected
bands was always stronger when OMVs were loaded as antigen,
indicating that the immune response was mainly directed against
surface-associated structures highly abundant in OMVs.
Immunization with an OMV Mix Induces a
Protective Immune Response
We used the infant mouse model to investigate whether the
induced humoral immune response also results in protection
against a V. cholerae or ETEC infection (Schild et al., 2008,
2009; Bishop et al., 2010; Leitner et al., 2013). This indirect
protection assay was used, since adult mice are only successfully
colonized by these human pathogens after pretreatment with
antibiotics to decrease the bacterial gut flora. Therefore, the
offspring of immunized dams were challenged orally and the level
of protection was measured by the degree of colonization in the
small intestine. To allow a continuous transfer of Igs from the
immunized dams to the suckling offspring, the infected neonatal
mice were given back to their respective dams for the challenge
period. In order to gain challenge data for both enteric pathogens,
the offspring of each immunization group were divided into
two subgroups and challenged orally with V. cholerae or ETEC
using approximately 9 × 104 CFU/mouse. These infection doses
are at least 100-fold above the ID50 and have been used for
previous challenge experiments (Goldhar et al., 1986; Schild et al.,
2009; Roy et al., 2011; Leitner et al., 2013). In the case of a
challenge with V. cholerae, neonatal mice of the non-vaccinated
control group as well as of the EWT and E1msbB1eltA OMV
immunization groups were colonized at comparable levels of
around 105–106 CFU/small intestine (Figure 7A). In contrast,
neonatal mice from the V1msbB1ctxAB OMV and the OMV
mix group were completely protected from colonization with
V. cholerae or showed at least a 1000-fold reduction in their
colonization level (P < 0.05; Kruskal–Wallis test and post-hoc
Dunn’s multiple comparisons). Challenging neonatal mice from
dams of the non-vaccinated control group with an ETEC strain
resulted in a stable colonization with a median colonization level
of around 107 CFU/small intestine (Figure 7B), whereas neonatal
mice from dams immunized with either V1msbB1ctxAB, EWT
or E1msbB1eltA OMVs showed a significant 10-fold reduction
in the colonization level (P < 0.05; Kruskal–Wallis test and
post-hoc Dunn’s multiple comparisons). The highest reduction
in the colonization rate upon ETEC challenge was observed in
the OMV mix group. Here, a 100-fold reduction in viable CFU
counts/small intestine compared to the non-vaccinated control
group was observed.
V. cholerae OMVs Can be used for Heterologous
Expression of ETEC Surface Antigens
Based on the induction of a species-specific immune response as
described above, we hypothesized that OMVs derived from one
species and decorated with heterologously expressed antigens
from the other species could induce a cross-protective immune
response. Using V1msbB1ctxAB OMVs as antigen delivery
vehicle, we genetically engineered the strain to express either
the CFA/I fimbriae or the hybrid flagellin FlaA-FliC (H) on
these OMVs. For the latter case, flaA was deleted on top of the
V1msbB1ctxABmutant to avoid influence of the intrinsic major
flagellin FlaA. Furthermore, the hybrid flagellin was used to allow
an efficient transport of the flagellin to the outer membrane.
Presence of these surface antigens in OMV preparations was
verified by immunoblot analysis using the respective OMVs in
combination with an anti-CfaB or an anti-FliC antibody (Figure
S3). The amount of the heterologous expressed proteins was
approximately 3–5% of the protein composition of the analyzed
OMVs.
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FIGURE 7 | Challenge of neonates born to OMV immunized mice with
V. cholerae and ETEC. Shown are the numbers of recovered CFU/small
intestine for neonates born to mice immunized with V1msbB1ctxAB OMVs,
EWT OMVs, E1msbB1eltA OMVs, and an OMV mix as well as the
non-vaccinated control group, which were challenged with either V. cholerae
(A) or ETEC (B) (n = 11 for each group). When no bacteria were recovered,
the number of CFU was set to the limit of detection of 10 CFU/small intestine
(dotted line). The error bars indicate the interquartile range of each data set.
Significant differences between the data sets are indicated by asterisks
(P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s multiple comparisons).
In order to elucidate the protective potential of the CFA/I or
of the hybrid flagellin decorated V. cholerae OMVs, female mice
were intranasally immunized with these OMVs according to our
standard immunization protocol. Serum samples, fecal pellets as
well asmilk samples were collected throughout the immunization
study tomonitor the humoral and themucosal immune response.
No obvious differences could be detected in the temporal, total,
or the secretory immune response against V. cholerae or ETEC
compared to the V1msbB1ctxAB OMV immunization group,
representing the undecorated OMV type (data not shown).
Both immunization groups exhibited significantly higher IgG1
titers against V. cholerae OMVs compared to the non-vaccinated
control group (P < 0.05; Kruskal–Wallis test and post-hoc
Dunn’s multiple comparisons) (Figure 8A). In contrast, the
antibody response against ETEC OMVs was below the limit of
detection. Thus, the heterologous expression of ETEC antigens
on V. cholerae OMVs has no adverse effect on the induction of
a high-titer immune response against the OMV donor species,
but fails to induce a overall detectable immune response against
ETEC OMVs.
To investigate the induction of an immune response against
the heterologous antigens, we determined the IgG1 titers against
purified His-CfaB and His-FliC in sera of immunized and non-
vaccinated mice (Figures 8B,C). Besides the respective groups
immunized with the CFA/I or the hybrid flagellin decorated V.
cholerae OMVs, the E1msbB1eltA OMV immunization group
and the OMV mix group were also included in this analysis.
The group immunized with CFA/I decorated V. cholerae OMVs
showed a significant induction of the IgG1 titer against His-
CfaB compared to the non-vaccinated control group (Figure 8B)
(P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s multiple
comparisons). Additionally, a weak anti-CfaB response was
observed in some mice immunized with E1msbB1eltA OMVs,
whereas none was detected in the OMV mix group. In contrast,
all tested immunization groups (V1msbB1ctxAB1flaA hybrid
FlaA-FliC OMV-, E1msbB1eltAOMV immunization group and
the OMVmix group) showed a significant IgG1 response against
purified His-FliC compared to the non-vaccinated control group
(Figure 8C) (P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s
multiple comparisons). The anti-FliC titers in the E1msbB1eltA
OMV or OMV mix immunization groups were significantly
higher compared to the V1msbB1ctxAB1flaA hybrid FlaA-
FliC OMV immunization group (P < 0.05; Kruskal–Wallis
test and post-hoc Dunn’s multiple comparisons). In summary, a
detectable immune response against each of the heterologously
expressed antigens could be induced. In contrast to CfaB, which
does not seem to serve as an antigen in ETEC OMVs, FliC
represented a highly immunogenic structure of the OMV species.
We also analyzed the immune response against proteins present
in the OMVs and the antibody specificity raised against the
LPS structure by immunoblot and ELISA, respectively. Both
assays revealed no differences compared to the results of the
V1msbB1ctxAB OMV immunization group (data not shown).
In order to investigate whether the induced immune responses
confer protection against a V. cholerae or ETEC infection, we
orally challenged the offspring of the immunized dams according
to the infant mouse model described above (Figures 9A,B).
All non-vaccinated control mice were stably colonized with
median colonization rates of 105 or 107 CFU/small intestine
for V. cholerae and ETEC, respectively. In contrast, both
immunization groups challenged with V. cholerae showed a
significant reduction of their colonization rate or were completely
protected from colonization compared to the non-vaccinated
control group (Figure 9A) (P < 0.05; Kruskal–Wallis test and
post-hoc Dunn’s multiple comparisons). Challenging neonatal
mice of dams immunized with decorated V. cholerae OMVs
with ETEC resulted in a significant 10-fold reduction in the
colonization level, which has already been observed in the
V1msbB1ctxAB immunization group (Figure 9B) (P < 0.05;
Kruskal–Wallis test and post-hoc Dunn’s multiple comparisons).
Thus, neither the immunization of CFA/I nor the hybrid flagellin
decorated V. choleraeOMVs resulted in a higher reduction in the
colonization rate upon ETEC challenge.
Inhibition of Motility In vitro Correlates with the
anti-FliC Titer in Sera of OMV Immunized Mice
and Contributes to Protection In vivo
We recently demonstrated that protection of neonatal mice
from V. cholerae infection occurs through the inhibition of
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FIGURE 8 | Quantification of the immune response of V. cholerae OMVs
expressing ETEC surface antigens. (A) Depicted are the IgG1 titers in sera
collected at day 86 from mice intranasal immunized with V1msbB1ctxAB
CFA/I OMVs, V1msbB1ctxAB1flaA hybrid FlaA-FliC OMVs and from the
non-vaccinated control group to V. cholerae OMVs (n ≥ 8 for each group). The
error bars indicate the interquartile range of each data set and the hash key
that the result of the data set was below the limit of detection. Significant
differences between the data sets are indicated by asterisks (P < 0.05;
Kruskal–Wallis test and post-hoc Dunn’s multiple comparisons). (B,C) Shown
are the IgG1 titers to purified His-CfaB (B) and His-FliC (C) in sera collected at
day 86 from mice intranasal immunized with V1msbB1ctxAB CFA/I OMVs,
V1msbB1ctxAB1flaA hybrid FlaA-FliC OMVs, E1msbB1eltA OMVs, an OMV
mix, or the non-vaccinated control group (n ≥ 8 for each group). The error bars
indicate the interquartile range of each data set and the hash key that the
result of the data set was below the limit of detection. Significant differences
between the data sets are indicated by asterisks (P < 0.05; Kruskal–Wallis test
and post-hoc Dunn’s multiple comparisons).
bacterial motility by O antigen antibodies fromOMV immunized
dams, which bind to the LPS present in the outer membrane
sheath of the single polar flagellum of V. cholerae (Leitner
et al., 2013). Since motility is crucial for the efficient adhesion
of ETEC to intestinal cells (Haiko and Westerlund-Wikström,
2013) and based on the high anti-FliC levels in ETEC OMV
immunized mice, we hypothesized that blockage of ETECs’
flagella could also play an important role in protection against
ETEC infection. To test our hypothesis, we performed an
established in vitro motility assay in which pooled sera of OMV
immunized or non-vaccinated mice as well as flagellum specific
antibodies were mixed 1:2 ratio with a bacterial suspension of
a GFP expressing ETEC strain and examined by fluorescence
microscopy (Figure 10A) (Leitner et al., 2013). Motile bacteria
appeared as swirls or lines, whereas non-motile bacteria appeared
as bright dots. We also quantified the number of motile bacteria
per field in each image (Figure 10B). Sera from non-vaccinated
control mice served as control and did not result in any inhibition
of motility. Only sera from E1msbB1eltA OMV immunized
mice or the OMV mix group, which contain FliC antibodies,
FIGURE 9 | Challenge of neonates born to mice immunized with V.
cholerae OMVs expressing ETEC antigens. Shown are the numbers of
recovered CFU/small intestine for neonates born to mice immunized with
V1msbB1ctxAB CFA/I OMVs, V1msbB1ctxAB1flaA hybrid FlaA-FliC OMVs
as well as the non-vaccinated control group mice, which were challenged with
either V. cholerae (A) or ETEC (B) (n ≥ 11 for each group). When no bacteria
were recovered, the number of CFU was set to the limit of detection of 10
CFU/small intestine (dotted line). The error bars indicate the interquartile range
for each data set. Significant differences between the data sets are indicated
by asterisks (P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s multiple
comparisons).
as well as the commercially available antisera directed against
FliC resulted in complete blockage of motility. Neither serum
from V1msbB1ctxAB, nor V1msbB1ctxAB CFA/I immunized
mice reduced the motility of ETEC. Interestingly, we only
observed a slight reduction of the motility, when serum of
mice immunized with V1msbB1ctxAB1flaA hybrid FlaA-FliC
OMVs, containing FliC antibodies, was used for the in vitro
motility assay. This might be explained by the 10-fold lower anti-
FliC titer of the V1msbB1ctxAB1flaA hybrid FlaA-FliC OMV
immunization group compared to the E1msbB1eltA OMV
immunized group or the OMV mix group (Figure 8C). Thus,
we excluded the V1msbB1ctxAB1flaA hybrid FlaA-FliC OMV
immunization group for further analysis. In summary, our results
demonstrate that the inhibition of motility in vitro correlates with
the presence of an anti-FliC titer.
To determine whether anti-FliC antibodies might also play
a role in the protection against ETEC in vivo, we performed
a passive immunization study using the infant mouse model
Frontiers in Microbiology | www.frontiersin.org 11 August 2015 | Volume 6 | Article 823
Leitner et al. OMV vaccine against enteric pathogens
FIGURE 10 | Inhibition of motility in vitro correlates with the
presence of anti-FliC antibodies and contributes to protection
in vivo. (A) Representative images using ETEC mixed with
non-vaccinated control sera (a), sera of V1msbB1ctxAB OMV immunized
mice (b), sera of E1msbB1eltA OMV immunized mice (c), sera of the
OMV mix group (d), sera of V1msbB1ctxAB CFA/I OMV immunized mice
(e), sera of V1msbB1ctxAB1flaA hybrid FlaA-FliC OMV immunized mice
(f), and anti-FliC antibodies (g). The bacterial motility was visualized by
fluorescence microscopy. Motile bacteria appeared as swirls and lines and
non-motile bacteria as dots. Bars, 50µm. (B) Quantification of the
bacterial motility of ETEC cells in the presence of non-vaccinated control
sera, sera of V1msbB1ctxAB OMV immunized mice, sera of
E1msbB1eltA OMV immunized mice, sera of the OMV mix group, sera
of V1msbB1ctxAB CFA/I OMV immunized mice, sera of
V1msbB1ctxAB1flaA hybrid FlaA-FliC OMV immunized mice and
anti-FliC antibodies. Each symbol represents an independent experiment,
and the horizontal bar indicates the median of each data set. When no
bacteria were visible, the number was set to the limit of detection of 1
bacterium/field (dotted line). Significant differences between the data sets
are indicated by asterisks (P < 0.05; Kruskal–Wallis test and post-hoc
Dunn’s multiple comparisons). (C) Passive immunization of neonates born
to naïve dams using ETEC WT mixed with sera of the non-vaccinated
control group, sera of V1msbB1ctxAB OMV immunized mice, sera of
E1msbB1eltA OMV immunized mice, sera of the OMV mix group or
anti-FliC antibodies (n ≥ 6 for each group). The error bars indicate the
interquartile range of each data set. Significant differences between the
data sets are indicated by asterisks (P < 0.05; Kruskal–Wallis test and
post-hoc Dunn’s multiple comparisons).
(Figure 10C). Naive infant mice were subdivided into five groups
and challenged with a defined dose of EWT mixed with one
of the five antisera used in the motility assay, separately. The
level of protection was determined by the degree of colonization
in the small intestine after 24 h. Mice passively immunized
with either the sera from the non-vaccinated control group or
the V1msbB1ctxAB OMV immunized group showed a high
colonization of 105 CFU/small intestine, whereas mice passively
immunized with sera from the E1msbB1eltA group or the OMV
mix group showed a significantly reduction in their colonization
(P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s multiple
comparisons). The highest reduction in the colonization rate
upon ETEC challenge was observed when mice were passively
immunized with the commercially available anti-FliC antibody.
Here, we could demonstrate a 100-fold reduction in viable CFU
counts/small intestine compared to the non-vaccinated control
group (P < 0.05; Kruskal–Wallis test and post-hoc Dunn’s
multiple comparisons). To exclude the possibility that ETEC
CFUs are already altered in the inoculation mix upon presence
of anti-FliC sera, viability of ETEC was determined by plating for
CFU counts after 30min of incubation. No significant reduction
in CFU for anti-FliC sera treated samples compared to the PBS
control could be observed (Figure S4). Thus, the observed effects
cannot be explained by reduced viability upon contact with this
antisera. In summary, the inhibition of motility based on anti-
FliC antibodies contributes to the observed protection against
ETEC.
Discussion
Over the last years OMVs have been intensively studied as
experimental vaccine candidates against various Gram-negative
pathogens. Encouraged by the promising results, we herein
describe the first combined vaccine approach based on OMVs
derived from different OMV donor species namely V. cholerae
and ETEC. Naturally, these native OMVs are composed of large
amounts of fully endotoxic LPS with a hexa-acylated lipid A
moiety, which is a very potent activator of TRL-4 (Raetz and
Whitfield, 2002). Although this renders the LPS an effective
adjuvant, it mainly contributes to vaccine reactogenicity as an
excessive activation of the inflammatory response may result
in septic shock. Therefore, the reduction of the endotoxicity is
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an essential step toward a safe application of an OMV vaccine
candidate in humans. The LPS content can be reduced either
by detergent extraction, which is applied for the production of
the classical N. meningitides OMV vaccines (Fredriksen et al.,
1991; Oster et al., 2005) or by genetically detoxification of the
LPS (Van Der Ley et al., 2001; Fisseha et al., 2005; van der
Ley and van den Dobbelsteen, 2011). Recently, we investigated
genetically detoxified OMVs of V. cholerae and demonstrated
that the non-stimulatory LPS produced by the msbB mutant
strain retain sufficient antigenicity to serve as protective target
for vaccination. Based on these results, we genetically modified
the lipid A structure of ETEC by deleting the secondary lipid A
acyltransferase, MsbB, and analyzed the endotoxic activity of the
resulting strain. In concordance with V1msbB OMVs (Leitner
et al., 2013), OMVs derived from an E1msbB strain reduced
the induction of an inflammatory response by 50% compared
to EWT OMVs without affecting the induction of a protective
immune response.
In this study, we focused on mucosal immunization strategies
due to a simple administration and a robust induction of
secretory Ig titers. Since ETEC OMVs are tightly associated
with active LT (Horstman and Kuehn, 2000, 2002; Kesty et al.,
2004), which can cause severe adverse effects including facial
palsy, the safety of the intranasal delivery of the OMV vaccine
candidate was brought into question for human applications
(Mutsch et al., 2004; Lewis et al., 2009). Although a recent study
did not report any side effects using 5µg LT for intranasally
immunization of mice, an OMV vaccine candidate with active LT
is unlikely to be approved (Roy et al., 2011). Thus, we pursued our
immunization studies with an ETEC OMV vaccine candidate,
lacking the enzymatically active subunit eltA of LT on top of
the msbB deletion. The remaining B subunit in the ETEC OMV
vaccine candidate serves as an adjuvant as well as it may provide
cross-protection against V. cholerae due to the closely related
AB-toxins of these two pathogens (Clements and Finkelstein,
1978). In the case ofV. cholerae, it already has been demonstrated
that CT is not required as an adjuvant for successful V. cholerae
OMV immunization, since OMVs from a CT mutant are as
immunogenic and protective as VWT OMVs (Bishop et al.,
2010). Based on a recent report, which suggest that the CT of
V. cholerae could be associated with the OMVs, we used a CT
deficient and detoxified V. cholerae OMV donor strain in this
study (Chatterjee and Chaudhuri, 2011).
To test the immunogenic and protective properties of V.
cholerae as well as ETEC OMVs, we performed a nasopharyngeal
immunization study, wherein female BALB/c mice were
immunized either with OMVs derived solely from one species
or an OMV mix, and analyzed the protection resulting from this
acquired immunity. The immunization with V1msbB1ctxAB
OMVs, EWT OMVs, or E1msbB1eltA OMVs did not induce a
cross-protective antibody response against ETEC or V. cholerae,
respectively. In contrast, the use of an OMV mix resulted in a
robust immune response with protective efficacy against both
pathogens. Remarkably, this group showed a similar induction
pattern of the humoral as well as the secretory immune
response in comparison to the respective immunization group
receiving only a single OMV type (i.e., V1msbB1ctxAB OMVs,
E1msbB1eltAOMVs or EWTOMVs) and the respective coating
material. Furthermore, this group exhibited a protective immune
response against V. cholerae, which was comparable with the
V1msbB1ctxAB OMV immunization group as well as the
highest protective response against ETEC observed in this study.
Taken together, these results demonstrate that the OMV mix
has the ability to induce a protective high-titer species-specific
immune response against both pathogens, although just half of
the amount of V. cholerae or ETEC OMVs has been used for the
immunization compared to the immunization group receiving
only a single OMV type.
Surprisingly, the use of V1msbB1ctxABOMVs alone already
induced a so far uncharacterized protective mechanism against
ETEC colonization. In general, such a cross-protection was
observed previously and thought to be due to cross-reactive
antibodies targeting the conserved B-subunit of the respective
toxins (Peltola et al., 1991). However, we used a non-toxigenic
V. cholerae mutant in this study. Thus, a CTB dependent
mechanism explaining the 10-fold reduction of the ETEC
colonization level can be excluded. While the EWT OMV
or E1msbB1eltA OMV immunization groups stimulate the
induction of species-specific antibodies, this cannot be the case
for the V1msbB1ctxAB OMV immunization group, since we
have not observed a detectable antibody response against ETEC.
Thus, the mechanism of this protective immune response is
unlikely based on the induction of anti-ETEC OMV antibodies,
but might be explained by antibody-independent mechanisms.
This hypothesis can be further encouraged by the passive
protection study, where the anti-V1msbB1ctxAB OMV sera
did not affect the colonization efficiency of ETEC in the small
intestine.
In an alternative approach, V. cholerae OMVs decorated
with the ETEC-specific antigens CFA/I or FliC were tested
for the induction of a cross-protective immune response. Both
antigens have been suggested as vaccine determinants and several
studies have demonstrated their protective effects (Ahrén and
Svennerholm, 1982; Tacket et al., 1988; Freedman et al., 1998;
Roy et al., 2009a; Svennerholm, 2011). In general, we observed
a similar induction of the humoral and the secretory immune
response against V. cholerae compared to the V1msbB1ctxAB
OMV immunization group, but the titers against ETEC OMVs
remained below the limit of detection. Additionally, a detectable
immune response against the heterologously expressed antigens
could be observed and revealed FliC being a highly immunogenic
structure compared to CFA/I in ETEC OMVs. However, these
approaches have not resulted in an improved protection against
an ETEC challenge compared to a simple V. cholerae and ETEC
OMV mixture. Since this approach did not yield in an increased
protective immune response, we did not comprehensively
analyze the exact localization (surface-accessible or luminal)
of the heterologously expressed antigens, which might affect
immunogenicity. Furthermore, it could be speculated that
a larger amount of the heterologously expressed antigens
would have resulted in higher antibody titers against the
presented antigen and might have induced a cross-species
specific immune response with an improved protection against
an ETEC challenge. Furthermore, it is questionable if every
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foreign antigen is suitable for the incorporation into OMVs as
the immunogenicity of the delivery vehicle in comparison to
the presented antigen might be crucial for the induction of a
sufficient immune response against both. Thus, the development
of a high-titer immune response against the used surface
antigens was probably hampered by a higher immunogenicity
of V. cholerae OMVs compared to the heterologously expressed
antigens (Dhungyel et al., 2014).
Recently, we identified the O antigen being the dominant
protective antigen of the OMV based cholera vaccine candidate
and revealed a protection mechanism based on the inhibition
of motility (Leitner et al., 2013). Since motility is crucial for
the efficient adhesion of ETEC to intestinal cells (Haiko and
Westerlund-Wikström, 2013) and based on the high anti-FliC
levels in ETEC OMV immunized mice, we speculated that the
blockage of ETEC flagella could also play an important role
in protection against ETEC infection. In concordance with this
hypothesis, the sera of mice immunized with E1msbB1eltA
OMVs or the OMV mix blocked motility, while sera of the
non-vaccinated control group, the V1msbB1ctxABOMV or the
V1msbB1ctxAB CFA/I OMV immunization groups showed no
effect. If sera of mice immunized with V1msbB1ctxAB1flaA
hybrid flagellin OMVs were used an intermediate phenotype
was observed. Thus, we hypothesized that a certain titer
of anti-FliC antibodies targeting the major flagellin, FliC, is
crucial for the inhibition of motility. By using a defined
anti-FliC antiserum, we were able to confirm this hypothesis.
Furthermore, we could demonstrate that the observed inhibition
of motility correlates with the anti-FliC antibody titer as
those immunization groups, which efficiently blocked motility
showed a higher immune response against purified His-FliC
compared to the V1msbB1ctxAB1flaA hybrid flagellin OMV
immunization group. The crucial role of anti-FliC antibodies in
protection against ETEC infection is highlighted by the passive
immunization study. Sera containing a sufficient amount of
anti-FliC antibodies (e.g., E1msbB1eltA OMVs, the OMV mix
or the anti-FliC) are capable of reducing the colonization of
ETEC. Consequently, the inhibition of motility via anti-FliC
antibodies represents a relevant protection mechanism of an
OMV-based ETEC vaccine candidate. In the case of the OMV
mix group, which comprises anti-ETEC as well as anti-V. cholerae
OMV antibodies, we have observed a 100-fold reduction of the
colonization level in our primary immunization study. Thus, we
hypothesize that the 100-fold reduction of the ETEC colonization
is due to a combination of an antibody-dependent (ETECOMVs)
as well as an antibody-independent (V. choleraeOMVs) immune
response.
Although our results indicate that the major flagellin
represents a protective antigen of an OMV based ETEC
vaccine, flagellar organelles have previously been excluded in
the development of ETEC vaccines due to their high variation
in H serotypes and the assumption that only variant instead of
highly conserved FliC regions are exposed. Nonetheless, these
highly conserved FliC regions are potent stimuli of the immune
response and mice immunized with a full-length flagellin of one
serotype have been significantly protected from a subsequent
challenge with an ETEC strain expressing another flagellin
serotype (Roy et al., 2009a,b). Thus, our findings support
these results and open a future direction in the ETEC vaccine
development including a flagellin, which would engender an
immune response directed against the highly conserved regions
of the antigen. Therefore, ETEC OMVs can be seen as an
attractive vaccine alternative, since they stimulate the immune
system with a combination of multiple antigens including
FliC, resulting in a protective antibody response. This idea is
further emphasized by recent immunoproteomic studies, which
demonstrated that the immune response to ETEC is quite
complex and involves the recognition of multiple proteins (Roy
et al., 2010). Thus, the inclusion of various antigenic components
should be the focus of an efficient broadly protective ETEC
vaccine. Hence, OMVs represent ideal vaccine candidates, which
can be easily isolated with anymodifications from different donor
species and combined in various OMV mixtures. Based on the
results of this study, the use of such a combined OMVmixture is
highly recommended as the OMVmix group represents the only
immunization group inducing a protective immune response
against both pathogens. It could be speculated that the protective
immune response might be even more pronounced by adjusting
the ratio of the respective OMVs for immunization based on
their immunogenicity. Furthermore, this idea could be extended
to develop a broadly protective OMV vaccine candidate against
several Gram-negative pathogens by combining their OMVs.
Thus, the results of this study not only provide first steps toward
an inexpensive broad-spectrum OMV vaccine candidate against
V. cholerae and ETEC, but also against other Gram-negative
pathogens of interest.
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